YD Bio (YDES) Receivables (2024 - 2025)
YD Bio (YDES) posted quarterly Receivables of $459.0 billion for Q4 2025, up 343.46% year-over-year from $103.5 billion in Q4 2024, and up 452545497.95% quarter-over-quarter from $101430.0 in Q2 2025.
YD Bio (YDES) Receivables (2024 - 2025) Analysis & Trends
YD Bio (YDES) has reported Receivables for 2 consecutive years, with $459.0 billion the latest figure, recorded in Q4 2025.
- In Q4 2025, Receivables rose 343.46% year-over-year to $459.0 billion; the TTM figure through Dec 2025 stood at $459.0 billion (up 343.46% YoY), while the FY2025 annual figure was $459.0 billion, up 343.46% from the prior year.
- Receivables grew to $459.0 billion in Q4 2025 per YDES's latest filing, from $101430.0 in the prior quarter.
- Across five years, Receivables topped out at $459.0 billion in Q4 2025 and bottomed at $101430.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.56 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 65.72 Bn | 60.53 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.75 Bn | 53.61 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.59 Bn | 10.19 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.63 Bn | 26.47 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.40 Bn | - | - |
| 10 | YD Bio | 316.92 Mn | 310.91 Mn | - | 459.02 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 459.02 Bn |
| Jun 30, 2025 | 101,430.00 |
| Dec 31, 2024 | 103.51 Bn |